Radiotherapy in the management of Kaposi's sarcoma: Comparison of 8 Gy versus 6 Gy
dc.contributor.author | Yıldız, Ferah | |
dc.contributor.author | Genç, Mine | |
dc.contributor.author | Akyürek, Serap | |
dc.contributor.author | Cengiz, Mustafa | |
dc.contributor.author | Özyar, Enis | |
dc.contributor.author | Selek, Uğur | |
dc.contributor.author | Atahan, I. Lale | |
dc.date.accessioned | 2020-03-26T17:04:08Z | |
dc.date.available | 2020-03-26T17:04:08Z | |
dc.date.issued | 2006 | |
dc.department | Selçuk Üniversitesi | en_US |
dc.description.abstract | Objective: To evaluate prospectively the efficacy of a single fraction of high-dose radiotherapy in patients with Kaposi's sarcoma. Patients: Between 1994 and 2004, 47 patients with Kaposi's sarcoma were treated at Hacettepe University, Department of Radiation Oncology. Thirteen (28%) patients received chemotherapy before radiotherapy and were referred due to recurrent or progressive disease or intolerance to chemotherapy. All lesions were treated locally with a 2-3-cm safety margin with 4-6-MeV electron beams. Radiotherapy consisted of a single fraction of 8 Gy in the first four years and 6 Gy thereafter. Results: The male:female ratio was 4:1. The median age was 61 years (range 18-87). Eight out of 47 patients (17%) had an underlying immunocompromised state, and one had a previous diagnosis of Hodgkin's disease. Of 203 fields treated, 51 and 152 fields were treated with 8 Gy and 6 Gy, respectively. Overall response rates (RR) at 12 months for 8- and 6 Gy were 93% and 86%, which were not statistically different. However, the difference between complete RRs at 12 months (93% and 60% for 8 Gy and 6 Gy respectively) was significant (p < 0.0001). Progression-free survival and reirradiation rates were not significantly different. Side effects were tolerable in all but three patients with grade 2-3 fibrosis and edema. Conclusion: Radiotherapy is an effective mode of treatment for Koposi's sarcoma, and a single dose of 8 Gy is more effective in terms of complete RR compared to 6 Gy, though overall response and progression-free survival rates were similar. | en_US |
dc.identifier.endpage | 1139 | en_US |
dc.identifier.issn | 0027-9684 | en_US |
dc.identifier.issue | 7 | en_US |
dc.identifier.pmid | 16895284 | en_US |
dc.identifier.scopusquality | Q1 | en_US |
dc.identifier.startpage | 1136 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12395/20636 | |
dc.identifier.volume | 98 | en_US |
dc.identifier.wos | WOS:000239195600012 | en_US |
dc.identifier.wosquality | Q2 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | NATL MED ASSOC | en_US |
dc.relation.ispartof | JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.selcuk | 20240510_oaig | en_US |
dc.subject | Kaposi's sarcoma | en_US |
dc.subject | radiotherapy | en_US |
dc.subject | single fraction | en_US |
dc.title | Radiotherapy in the management of Kaposi's sarcoma: Comparison of 8 Gy versus 6 Gy | en_US |
dc.type | Article | en_US |